REDWOOD CITY, CA / ACCESSWIRE / January 17, 2023 / Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, announced it has signed an agreement with a number one group ‎purchasing organization (“GPO”) for national distribution of its cardiac monitoring solutions, Bioflux® and BiotresTM.
Each Bioflux and Biotres are designed for cardiologists to diagnose and monitor their patients remotely. GPO’s are entities comprised of companies organized to buy materials or supplies from vendors in larger volumes to realize efficiency. On this case, the GPO is comprised of a whole lot of small, independent US hospitals, private ‎clinics, and medical offices that purchase medical devices and supplies at scale.
“Becoming a newly featured vendor of state-of-the-art cardiac monitoring solutions with a number one medical device & supplies GPO, will boost our visibility industry-wide,” said Waqaas Al-Siddiq, Ph.D., Biotricity Founder, Chairman and CEO. “We anticipate increasing revenue growth across 2023 through the expansion of our products’ availability through these latest sales channels.”
About Biotricity
Biotricity is transforming the healthcare market by bridging the gap in distant monitoring and chronic care management with a give attention to cardiology. Physicians and patients trust Biotricity’s unparalleled standard for preventive and private care, including diagnostic and post-diagnostic solutions for chronic conditions. The corporate develops comprehensive distant health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com and follow us on Twitter and LinkedIn.
Necessary Cautions Regarding Forward-Looking Statements
Any statements contained on this press release that don’t describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “consider,” “intend,” “seek,” “project,” or “goal” or the negative of those words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals referring to the design, development and commercialization of Bioflux or any of the Company’s other proposed services or products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime through which the Company operates or intends to operate and (v) the assumptions underlying or referring to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements should not meant to predict or guarantee actual results, performance, events or circumstances and might not be realized because they’re based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to quite a few risks and uncertainties and other influences, a lot of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of this of those risks and uncertainties. Aspects that will influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to acquire additional financing, the numerous length of time and resources related to the event of its products and related insufficient money flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other aspects are identified and described in additional detail within the Company’s filings with the SEC. There can’t be any assurance that the Company will ever grow to be profitable. Throughout the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements with the intention to reflect any event or circumstance that will arise after the date of this release.
Investor Relations Contacts
investors@biotricity.com
SOURCE: Biotricity Inc.
View source version on accesswire.com:
https://www.accesswire.com/735421/Biotricity-Signs-with-Top-5-Group-Purchasing-Organization-Potential-for-Higher-Sales-Volume-in-2023
